![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Clinical Trial Participation Brings Hefty Travel Burden, Study Finds
Clinical Trial Participation Brings Hefty Travel Burden, Study Finds
May 7, 2018
A study published in The Oncologist found that patients who enroll in clinical trials for treatment experience a heavy travel burden.
The study analyzed the data of 1,600 patients who enrolled in a clinical trial between 1993 and 2014, measuring the distance they traveled from their home to the site of the study and finding that, overall, patients traveled a median distance of 25.8 miles.
Patients in NIH-sponsored studies had to go even greater distances, 39.4 miles on average, and patients in phase 1 studies had to travel farther than any other type, traveling a median of 41.2 miles to participate, the study said.
“Future work will need to examine the total out-of-pocket expenses assumed by patients across multiple academic centers to account for regional and geographic variability of trial participation,” the study authors said.
Upcoming Events
-
21Oct